Holen Sie sich die Stockscreener-App
157.24
1.14%
1.77
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
36,259 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Blue Owl Capital Holdings LP - MarketBeat
Palvella Therapeutics COO Kathleen Goin Executes Stock Option Exercises and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $654,807.42 in Stock - MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates - kalkine.ca
Palvella (PVLA) Latest Quarter: EPS Comes in Below Forecast in the Available Record; Share Response: Shares Fall 6.03% for the Current SessionConsensus Forecast Report - vinanet.vn
Lisanti Capital Growth LLC Purchases Shares of 42,975 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel - Seeking Alpha
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands - MarketBeat
PRUDENTIAL FINANCIAL INC Establishes New Position in Palvella Th - GuruFocus
Palvella at Canaccord Genuity’s 46th Annual Growth Conference: launch prep By Investing.com - Investing.com Canada
Palvella (PVLA) Q2 2026 Earnings Call Transcript - AOL.com
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Australia
Palvella Therapeutics, Inc. (PVLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Palvella Therapeutics, Inc. $PVLA Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval? - Yahoo Finance
Jennison Associates Expands Palvella Therapeutics (PVLA) Stake i - GuruFocus
Palvella Therapeutics Inc (PVLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Q3 EPS Estimate for Palvella Therapeutics Cut by Analyst - marketbeat.com
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
High-Risk Warning for Investors in Palvella Therapeutics Securities - The Globe and Mail
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call - Sahm
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270 - moomoo.com
Palvella Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PVLA) 2026-08-05 - Seeking Alpha
Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $207 - Moomoo
Palvella details QTORIN progress and Nasdaq uplisting milestones - The Globe and Mail
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Palvella Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Palvella Therapeutics Inc (PVLA) (Q2 2026) Earnings Call Highlights: Strong Phase 3 Data and ... - finance.yahoo.com
Palvella Therapeutics Q2 Earnings Call Highlights - MarketBeat
Palvella Therapeutics, Inc.Common Stock (PVLA) Stock Price, News, Quote & History - FinancialContent
Earnings call transcript: Palvella shares rise on q2 2026 launch progress - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Posts Quarterly Earnings Results, Misses Expectations By $0.35 EPS - MarketBeat
PVLA: Positive phase III data, rolling NDA, and strong cash position drive launch readiness and pipeline growth - TradingView
PVLA: QTORIN rapamycin advanced toward FDA approval with strong phase III data, robust cash, and launch readiness - TradingView
Palvella Therapeutics Q2 Net Loss Widens - marketscreener.com
Palvella Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Palvella Therapeutics, Inc. (PVLA) Q2 FY2026 earnings call transcript - Yahoo Finance
Palvella Therapeutics Q2 net loss widens on higher expenses - TradingView
PVLA: Advanced NDA submission and clinical pipeline with $250.6M cash; net loss widened to $21.9M - TradingView
Earnings Flash (PVLA) Palvella Therapeutics Posts Q2 Net Loss $1.52 a Share, vs. FactSet Est of $1.07 Loss - marketscreener.com
Palvella Therapeutics: Q2 Earnings Snapshot - Barchart.com
Palvella Reports Q2 Net Loss and Advances QTORIN NDA Plans - Quiver Quantitative
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
All eyes on Palvella earnings as rare disease drug nears approval - Investing.com Nigeria
Arete Wealth Advisors LLC Makes New $2.18 Million Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Chardan Capital Upgrades Palvella Therapeutics (NASDAQ:PVLA) to Strong-Buy - MarketBeat
Palvella Therapeutics Chief Scientific Officer Jeff - GlobeNewswire
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing - The Manila Times
Palvella Therapeutics (PVLA) Holds Steady Near Key Resistance LevelDelta Hedging - dars.gov.et
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 - markets.businessinsider.com
Palvella Therapeutics to Host Second Quarter 2026 Financial - GlobeNewswire
Palvella Therapeutics Inc (PVLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Palvella Therapeutics Inc (PVLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Palvella Therapeutics Market Sentiment - Benzinga España
Palvella Therapeutics Inc (PVLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palvella Therapeutics Inc (PVLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PVLA|Palvella Therapeutics Inc|Price:141.780|Chg%:+3.770 - TradingKey
Palvella Therapeutics, Inc. $PVLA Stock Position Increased by First Light Asset Management LLC - MarketBeat
TradingKey - TradingKey
Palvella Therapeutics Inc (PVLA) Cash Flow - TradingKey
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):